Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH
ALG-055009 dose groups met the primary endpoint with statistically significant reductions in liver fat at Week 12 as measured ...
Aligos posts initial mid-stage trial results for MASH candidate
Aligos Therapeutics (ALGS) stock slips as company releases Phase 2a results for liver drug ALG-055009 in MASH. Read more here ...
FierceBiotech18h
Aligos' MASH prospect slashes liver fat in phase 2, but stock drops anyway
Aligos Therapeutics is heralding a midstage win in metabolic-dysfunction associated steatohepatitis (MASH) after three ...
Aligos Therapeutics' ALG-055009 Trial Met Primary Goal In MASH; In Talks For Fund; Stock Drops
Aligos Therapeutics, Inc. (ALGS), a clinical stage biopharmaceutical company focused on liver and viral diseases, announced Thursday ...
The EMBO Journal22h
Liver protects neuron viability and electrocortical activity in post-cardiac arrest brain injury
The liver function in post-cardiac arrest brain injury is not known and was investigated in a pig model of global cerebral ...
Frontiers22h
Multimodal magnetic resonance imaging of brain networks during cognitive impairment
Keywords: Multimodal MRI, Cognitive impairment, Alzheimer's disease, Diffusion tensor imaging (DTI), Functional MRI (fMRI), Structural MRI, Brain networks, Magnetic resonance spectroscopy (MRS), ...